Skip to content

Falls Among the Older Patients Treated for Cancer in Normandy's Outclinics: Screening and Prevention

CHUtes Chez Les Personnes Agées traitées Pour Cancer Dans Les HOpitaUx Normands : repérage et Prévention

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06504628
Acronym
CHUPACHOUP
Enrollment
328
Registered
2024-07-17
Start date
2024-09-16
Completion date
2025-02-15
Last updated
2025-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aged Patients Treated for Cancer in Outclinics

Keywords

aged, outpatients, cancer, accidental falls

Brief summary

The French Plan National AntiChute (published on February 21, 2022) and international recommendations on falls prevention (Age Ageing,September 2022) recommend identifying the risk of falling in people aged 65 and over, at least once a year during a follow-up consultation. The presence of chronic illness such as cancer increases the risk for falling. Recommendations suggest targeted preventive interventions according to the risk level, and early reassessment at 3 months in case of high risk. This study consists of a cross-sectional survey conducted during a week dedicated to patient safety (September 16-20, 2024), to identify the prevalence of patients at high risk for falling, requiring enhanced care. The relation between high risk for falling and social and oncological characteristics will be studied. A 3-month telephone follow-up will identify any obstacles to implementing the recommendations in this high-risk group. This multicenter cross-sectional prospective study is exploratory.

Interventions

DIAGNOSTIC_TESTscreening risk for falling and identifiy the risk level low-intermediate-high

3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step. if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk

DIAGNOSTIC_TEST3 mnth-follow-up

patient's phone call, and data collected from electronic medical record

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged 65 or over * undergoing treatment for cancer or hematological malignancy (oral or injectable systemic treatment, radiotherapy) * covered by health insurance * having read the information document and no objection * French-speaking * Autonomous ( with occasional assistance with instrumental daily activities),

Exclusion criteria

* refusal to participate * unable to communicate * dependent (requiring geriatric care)

Design outcomes

Primary

MeasureTime frameDescription
prevalence of each of the three levels of fall-riskDay 1describe the distribution of patients in mild, intermediate and high risk for falling

Secondary

MeasureTime frame
look for association between high-risk categorization and rural place of residence, gender, age bracket (65-74 and 75 and over), investigating center, type of cancer (location).Day 1
Describe the rate of high-risk patients who will have benefited from (full or partial) implementation of recommended interventions according to 3-month follow-up.3 mnths
among high-risk patients followed up at 3 months, look for an association between the absence ofimplementation of recommendations and social, medical characteristics and motive3 mnths
describe the Average number of STOPPFALL medications per patient. Rate of patients with at least one oncologydrug listed as a fall risk (CIPN), in the 3 fall risk categoriesDay 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 19, 2026